Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

6.580
-0.040-0.60%
Volume:4.46M
Turnover:30.50M
Market Cap:6.34B
PE:-20.05
High:7.130
Open:6.900
Low:6.550
Close:6.620
Loading ...

Ascletis Pharma's Application for Plaque Psoriasis Drug Cleared by US FDA

MT Newswires Live
·
22 May

BRIEF-Ascletis Announces U.S. FDA Clearance Of Ind Application For Its Oral Small Molecule Il-17 Inhibitor, ASC50, For The Treatment Of Psoriasis

Reuters
·
22 May

BRIEF-Ascletis Pharma Says US FDA Cleared IND Application For Oral Small Molecule IL-17 Inhibitor, ASC50

Reuters
·
22 May

Ascletis Announces U.S. FDA Clearance of Ind Application for Its Oral Small Molecule Il-17 Inhibitor, Asc50, for the Treatment of Psoriasis

THOMSON REUTERS
·
22 May

Ascletis Pharma Inc - Phase I Trial Dosing Expected to Start in Q3 2025

THOMSON REUTERS
·
22 May

Ascletis Pharma Inc. Announces FDA Clearance for Phase I Trial of ASC50, a Promising Oral IL-17 Inhibitor for Psoriasis Treatment

Reuters
·
22 May

Ascletis Pharma Inc - U.S. FDA Clearance of Ind Application for Oral Small Molecule Il-17 Inhibitor, Asc50

THOMSON REUTERS
·
22 May

Ascletis Pharma Inc. Conducted Annual General Meeting

Reuters
·
22 May

Ascletis Doses First Patients for US Trial of Obesity Drug Combo

MT Newswires Live
·
21 May

HK Movers | HK's Biotech Shares Soar. Asymchem up 15%; Laekna up 13%; Ascletis, CanSinoBIO up 9%

Tiger Newspress
·
21 May

BRIEF-Ascletis Announces First Participants Dosed In A U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, And Semaglutide For The Treatment Of Obesity

Reuters
·
20 May

Ascletis Pharma Initiates U.S. Clinical Study Combining ASC47 and Semaglutide for Obesity Treatment

Reuters
·
20 May

Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule ThrΒ Agonist, Asc47, and Semaglutide for the Treatment of Obesity

THOMSON REUTERS
·
20 May

Ascletis Pharma Inc - Topline Data From Study Expected in Q4 2025

THOMSON REUTERS
·
20 May

HK Movers | HK's Biotech Shares Soar. Cstone Pharma Soars 20%; RemeGen up 10%; Ascletis up 6%

Tiger Newspress
·
20 May

HK Movers | HK's Biotech Shares Pull Back. Alphamab, Cstone Pharma, Ascletis down about 10%; Immuneonco, Laekna down over 9%

Tiger Newspress
·
12 May

Ascletis Pharma to Present Results of Preliminary Studies on Anti-Obesity Drug

MT Newswires Live
·
06 May

Ascletis Pharma's Phase 1B Trial for Obesity Tablets Showed Favorable Safety Results

MT Newswires Live
·
23 Apr

HK Movers | Biotech Stocks Rally With Zai Lab up 8%

Tiger Newspress
·
23 Apr

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30 and Submission of 13-Week Phase Iia Study Protocol to FDA

THOMSON REUTERS
·
23 Apr